Instructions and definitions available here. Frequently asked questions available here.

Study Title:

Investigator:

Sponsor (if applicable):

New Study Checklist

CRA:									
Coordinator:									
Financial Manager:									
IRB#:									
				Date	Date				
Item	Yes	No	N/A	Received	Completed	Comments			
STUDY ID / GENERAL INFORMATION									
Is your study industry or foundation sponsored*?									
Is your study government (NIH, DOD, CDD, etc.) sponsored?									
Is your study intramurally sponsored (Alliance, COM, Department, CCTS, etc.)?									
Center for Clinical and Translational Science A service request form is required if utilizing CCTS s you and provide a budget estimate and letter of agree	ervices	s (<u>http.</u>	://www	ccts.uky.edu/ccts					
Budget estimate and letter of agreement executed with CCTS?									
Cancer Patients (if applicable)									
Does the study involve enrolling cancer patients? If so, contact the Markey Cancer Center Research Network at (859) 218-4062.									



received?

Has Markey Cancer Center approval been

				Date	Date	
Item	Yes	No	N/A	Received	Completed	Comments

SPACE / LABORATORIES / SITE INFORMATION									
Site Selection and Initiation*									
Has the site selection visit been completed?									
Has the site selection letter been received?									
Is UK Healthcare Ambulatory space being used to conduct research participant evaluations?									
If yes, are room fees applicable for the use of this space?									
If yes, have the room fees been included in the budget?									
Veteran's Affairs (VA) Patients (if applicable)									
Does the study involve enrolling patients from the VA? If so, contact the VA for additional information regarding research.									
Has VA approval been received?									
Laboratories									
Are UK Healthcare laboratories being used?									
Are any outside laboratories being used?									
Are all laboratories **CAP/CLIA certified?									
Will outside laboratory results be entered into Epic?									
If the study uses test results from a non-CLIA certified laboratory, do you agree that the									
results will not be used to guide clinical care?									
External Sites (if applicable) This applies to res Contact UK College of Medicine Office of Research									
Does your study involve an external site?									

				Date	Date				
Item	Yes	No	N/A	Received	Completed	Comments			
			ı		T				
Does the external site's contract with UK allow research?									
Has indemnification of the external site been addressed?									
Will data be shared between the sites?									
Home Health Exemption (if applicable)									
Does the study involve going into a patient/participant's home? If so, you may need a home health exemption. Contact UK Office of Legal Counsel at ukofficeoflegalcounsel@uky.edu for assistance.									
Has a Home Health Exemption been received?									
COI / CDA / NDA / MTA / DUA									
Conflict of Interest (COI) Pls are responsible for ensuring that significant final other required disclosure forms not vetted by the instance.					appropriately disclo	osed in IRB applications and any			
Has the Office of Sponsored Projects Administration (OSPA) been contacted for COI disclosures, https://www.research.uky.edu/office-sponsored-projects-administration/conflict-interest ?				·					
Confidentiality Agreement (CDA/NDA)* Most sponsors require a signed confidentiality agreement prior to sharing a protocol. Pls are not authorized to sign CDAs. The Office of Technology and Commercialization has sole signatory authority. Information on where to send draft CDAs can be found at https://www.research.uky.edu/office-technology-commercialization/transfer-agreements .									
Fully executed CDA received?									
Clinical Trial Agreement (CTA)* CTAs are negotiated by the Office of Sponsored Pro	ojects A	\dmini.	stration	(OSPA). PIs can	not sign CTAs. OS	PA has sole signatory authority.			
Fully executed CTA?									

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
Non-Indemnification It is the responsibility of the principal investigator to initiate the non-indemnification review process for all eligible clinical trials, as defined here. If an investigator does not forward a study for review that qualifies for Inclusion in the Indemnification Process and a problem occurs and a claim is made, the University is not obligated to defend the investigator. Contact (859) 218-6610 with any questions regarding the non-indemnification submission/review process. If your agreement is industry/externally sponsored, please contact OSPA if you have questions about whether your study qualifies for non-indemnification review.										
Have you contacted UK Healthcare Risk Management Committee about non- indemnification review?										
Data/Material Sharing Information can be found at https://www.research.uky.edu/office-technology-commercialization/transfer-agreements including appropriate contact information regarding data/material sharing.										
Is the study sharing confidential information outside of UK and/or is UK receiving confidential information from outside UK?										
Material Transfer Agreement (MTA) Information can be found at https://www.research.uky.edu/office-technology-commercialization/transfer-agreements including appropriate contact information regarding MTAs.										
Will you be transferring materials (specimens, cell lines, mice, plants, etc.) outside of UK?										
If so, has an MTA been executed? Will you be transferring data (fully deidentified, a limited data set, or Protected Health Information (PHI)/Personally Identifiable Information (PII)) outside of the University?										
If yes, has a Data Use Agreement (DUA) been executed? If yes, did the DUA describe data destruction										
guidance? If no, is the data set a limited data set?										
If no, is the data set de-identified?										
Will the data be stored at UKHC?										

Г	1			T	T					
				Date	Date					
Item	Yes	No	N/A	Received	Completed	Comments				
If yes, has the request been reviewed by										
UKHC IT to determine if technology resources										
are required to support data storage?										
BUDGET / Co	OVER	RAGE	E ANA	ALYSIS / BILL	ING REVIEW					
Sponsor Budget Development/Negotiation*										
Sponsors will typically send a budget template to guide budget negotiations. The budget should always be prepared using actual costs.										
Along with patient care costs, o PI effort, coordinator effort, regulatory support, grants management support, IDS, ancillary costs, patient										
stipend, long-term storage costs, IRB fees, pass-thru costs (protocol amendments, SAEs, IND safety reports, protocol violations, etc), and										
indirect costs need to be included.		-								
The F&A rate for indirect costs is determined by OS	PA. Gı	ıideline	es for F	-&A can be found	<u>here</u> ; any question	s about the appropriate F&A rate				
should be directed to <u>OSPA</u> .				T	1	,				
Sponsor budget approved?										
eIAF completed?										
https://www.research.uky.edu/uploads/instructi										
ons-completing-eiaf-myuk										
Coverage Analysis and Billing Review										
Submit a service request form for coverage analysis	at: <u>htt</u>	ps://cc	tsdata.	.uky.edu/members	ship/					
Has the study been submitted to the CRSO										
MCA team for review?										
Did the MCA team determine if the study is										
qualifying?										
Billing Review: If a Clinical Research study con	tains it	ems a	nd se	rvices provided a	t any UKHC faci	lity or by UKHC providers (i.e.,				
Labs, Scans, Examinations), the research study										
segregation.					,	3 -				
A clinical research study (clinical trial or research	h with	billab	le iten	ns) must be in the	e CTMS system a	and is send to the EHR (Epic)				
system after the billing review or CA has been of				,	,	(_p)				
Do you have a designated staff member who		- 2								
reviews the billing in Epic and maintains the										
records in the CTMS system?										
1000140 III tilo O I WIO Oyotoiii:	1			1	<u> </u>	<u>l</u>				

Item	Yes	No	N/A	Date Received	Date Completed	Comments					
OnCore All studies meeting the NIH definition of a clinical trial need to be built into Oncore regardless of the sponsor. To review the NIH definition of a clinical trial go to https://grants.nih.gov/policy/clinical-trials/definition.htm . Does the study pood to be built into OnCore?											
Does the study need to be built into OnCore? Please contact CRSOStudyAssist@uky.edu with any questions.											
Has the study been built in OnCore? Please submit studies at											
https://www.research.uky.edu/clinical- research-support-office											
After the Billing review or CA present Door			1		1						
After the Billing review or CA process - Does the study have any services or procedures											
that will occur at a designated UKHC facility or											
provided by any UKHC provider? If so, the											
study must be included in Epic. If you have											
questions about this process please contact											
the CRSO at CRSOStudyAssist@uky.edu											
INVESTIGATIONA	L DR	RUG /	DEV	ICE AND REL	ATED SERVI	CES					
Investigational Drug Studies and IDS-related	servi	ces (i	f appl	icable)							
Does the study use an investigational drug? If											
yes, contact IDS@uky.edu to request IDS											
support and agreement that support will be											
provided per the study protocol. If your study includes an investigational drug,											
have you obtained the FDA approval? A											
treatment could be a drug, medical device, or											
biologic, such as a vaccine, blood product, or											
gene therapy. Drug developers, or sponsors,											
must submit an Investigational New Drug											
(IND) application to FDA before beginning											
clinical research.											

Item	Yes	No	N/A	Date Received	Date Completed	Comments			
			1		ı				
Do you need an IND based on the FDA rules?									
There are three IND types: An Investigator									
IND, Emergency Use IND (21CFR, Sec.									
312.23 or Sec. 312.20), AND Treatment IND									
is submitted for experimental drugs showing									
promise in clinical testing for serious or									
immediately life-threatening conditions. There									
are two IND categories: Commercial &									
Research (non-commercial)									
If your study is exempt, please document it as									
set forth by the FDA regulations: To be									
exempt [21 CFR 312.2(b)], 1) the drug must									
be lawfully marketed in the US, 2) the study									
cannot be intended to support a new									
indication or other significant change in									
product labeling, 3) the study cannot be									
intended to support a significant change in									
advertising for the drug or be used to promote									
the drug. During the billing review and study									
submission to the CRSO please indicate if									
your study is IND exempt.									
Is IDS providing support for your study?									
Device Studies (if applicable)									
Does your study involve a device? If so, you									
may need to go through the Celerian Group									
Company (CGS) device notification process.									
Contact renee.hensley@uky.edu (Please note									
this will require annual reapproval)									
	CMS approval needed for: Studies with the Category A are approved for coverage of routine services only. Studies with the Category B are								
approved for coverage of the Category B device and related services, and routine services.									

If your study is NOT submitted and approved under the CMS guidelines, the study is considered to be Non-Qualifying for coverage of routine costs under the CMS NCD 310.1. You can still conduct your study but the coverage by insurances will be limited.

Ensure that you (your sponsor) follows the FDA requirements for Medical devices are classified into Class I, II, and III. Regulatory control increases from Class I to Class III. The device classification regulation defines the regulatory requirements for a general device type. Most Class I devices are exempt from Premarket Notification 510(k); most Class II devices require Premarket Notification 510(k); and most Class

				Date	Date						
Item	Yes	No	N/A	Received	Completed	Comments					
					•						
III devices require Premarket Approval. A description "Classification of Medical Devices."											
Have you received approval for use of your research device at UK?											
Does your device need engineering review?											
REGULATORY											
Certificate of Confidentiality All NIH sponsored clinical trials automatically fall und by the NIH must request a certificate of confidentialit 56-ori summary on coc.pdf.											
Does your study have a certificate of confidentiality?											
If yes and data is entered into Epic, is a system in place to assure confidentiality?											
Institutional Review Board (IRB) If your study involves human subjects either IRB approval or an IRB waiver must be obtained.											
Are you using the UK IRB?											
Are you using a central IRB?											
If a central IRB, do you have a reliance agreement in place?											
Has IRB approval been received?											
Does your research project involve nurses at UK Healthcare as subjects, or is it being conducted by a nurse(s) from UK Healthcare?											
If yes, contact the <u>UK Nursing Research</u> Council before conducting the study. A											
student who is also a UK employee but is not doing their research at UKHC does not need NRC approval.											
Clinical Trials.gov											
Does your study need to be registered on											
ClinicalTrials.gov? If you have any questions											

Item	Yes	No	N/A	Date Received	Date Completed	Comments
Kom	100	110	14// 1	110001100	Completed	Comments
about ClinicalTrials.gov, please contact <u>UK's</u>						
Clinical Trials Compliance Administrator						
If yes, what is the assigned NCT number						
(found within your ct.gov account)?						
Institutional Biosafety (IBC) (if applicable)						
Does the study need to be registered with the						
Institutional Biosafety Committee (IBC)? For						
more information,						
http://ehs.uky.edu/docs/pdf/bio_ibc_registratio						
n 0001.pdf						
Has IBC approval been received?						
Radioactive Material						
Does your study involve the procurement, use,						
storage and disposal of radioactive material						
and radiation-producing devices?						
If yes, visit						
https://www.research.uky.edu/office-research-integrity/irb-application-instructions-radiation-						
safety for more information.						
<u>salety</u> for more information.	<u> </u>					
Biobanking					,	
Will any biobanking be done as part of the research?						
If yes, has biobanking language been included						
in the consent?						
Genetic Testing	, .					
Will any genetic testing be performed?						
If yes, has genetic testing language been						
included in your consent?						

Item	Yes	No	N/A	Received	Completed	Comments
ltem	Yes	Nο	N/A	Date Received	Date Completed	Comments

TRAINING									
Human Subject's Protection (HSP)									
All key personnel working on studies involving human subjects must complete HSP training. https://www.research.uky.edu/office-research-									
integrity/human-subject-protection-hsp-training-fags									
Have all key personnel completed HSP									
training?									
Responsible Conduct of Research (RCR)									
All full-time faculty, staff, graduate students, and trainees (undergraduates, postdoctoral fellows, visiting scientists) who participate in									
research or creative work, including individuals supported in part or fully through research funding, grants, or contracts are required to									
complete the Responsible Conduct of Research (RCR) course initially and then every 2 years.									
Have all required key personnel completed									
RCR training?									
Good Clinical Practice (GCP) (if applicable)									
Individuals who are conducting research trials for drugs, biologics or devices should complete GCP training. GCP training is required for all									
NIH-sponsored studies and/or if you are using any CCTS services.									
Have all required key personnel completed									
GCP training?									
DOT/IATA (if applicable)									
The University requires all faculty, staff and students		are inve	olved ii	n any aspect of sh	ipping dangerous	goods (e.g., packing, labeling,			
transporting, etc.) to attend a DOT/IATA Initial Train	ing								
course.									
The initial course is held in a classroom setting so cl			nited a	nd pre-registratior	i is required. Regis	ter at			
https://ehs.uky.edu/classes/classes_env_0001.php#	dot ia	<u>ta</u> .			T				
Have all staff shipping dangerous goods									
completed DOT/IATA training?									
Institutional Biosafety (IBC) (if applicable)									
https://ehs.uky.edu/classes/	1				T				
Have all required key personnel completed									
IBC training?									